Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.49% gain on the day. On the ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

In trading on Tuesday, shares of AstraZeneca plc (Symbol: AZN) crossed below their 200 day moving average of $74.95, changing hands as low as $74.87 per share. AstraZeneca plc shares are currently ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...